Vantobra is an antibiotic used for treating long\-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis. Cystic fibrosis is an inherited disease in which thick mucus builds up in the lungs that allows bacteria to grow more easily, causing infections. P. aeruginosa is a frequent cause of infections in cystic fibrosis patients. Vantobra is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, tobramycin; however, Vantobra has a higher amount of the active substance. The reference medicine for Vantobra is Tobi.
Therapeutic Indication
Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Therapeutic Area (MeSH)
ATC Code
J01GB01
ATC Item
N/A
Pharmacotherapeutic Group
Antibacterials for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| tobramycin | N/A | tobramycin |
EMA Name
Vantobra (previously Tobramycin PARI)
Medicine Name
Vantobra (previously Tobramycin PARI)
Aliases
N/ANo risk management plan link.
